Trial
NCT03616821
Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
—
Condition
Ulcerative Colitis
Intervention
Brazikumab
Why stopped
Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-23